The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH

What Was Tested

This randomized controlled trial paper looks at Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).

Few studies have assessed the relationship between GH and mitochondrial function.

Who Took Part

The abstract describes 39 men taking part.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Tesamorelin and who got the comparison, which limits bias.

As a double-blind Tesamorelin study, the assignments were hidden from both participants and investigators until the end.

Some men received a placebo instead of Tesamorelin, giving a reference point.

PCr recovery after submaximal exercise was assessed at baseline and at 12 months.

What Was Measured

Few studies have assessed the relationship between GH and mitochondrial function.

Topics PubMed links to this paper include Exercise, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypopituitarism, Insulin-Like Growth Factor I, Obesity and Phosphocreatine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) in 39 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.